Kathryn Skelding

Professional Summary: Professor Kathryn Skelding

Professor Kathryn Skelding is a distinguished academic at the University of Newcastle, Australia, with a notable career in the field of medical sciences. Her expertise and contributions span across cancer research, molecular biology, and therapeutic development, positioning her as a respected figure in her discipline. Below is a detailed overview of her academic journey, research focus, and professional achievements based on publicly available information.

Academic Background and Degrees

Professor Skelding holds advanced qualifications in the biomedical sciences. While specific details of her degrees and institutions are not fully disclosed in accessible public records, her academic standing and contributions at the University of Newcastle affirm a robust educational foundation in molecular biology and related fields.

Research Specializations and Academic Interests

Professor Skelding’s research primarily focuses on cancer biology, with an emphasis on understanding molecular mechanisms underlying cancer progression and developing novel therapeutic strategies. Her work explores targeted therapies and the role of specific proteins in cancer cell behavior, contributing to advancements in personalized medicine.

Career History and Appointments

• Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia (current position based on public records)
• Active researcher and academic contributor within the Hunter Medical Research Institute (HMRI), affiliated with the University of Newcastle

Major Awards, Fellowships, and Honors

While specific awards and honors for Professor Skelding are not extensively documented in public sources, her sustained research output and academic role at a leading institution reflect recognition within her field. Any grants or fellowships associated with her projects at HMRI or the University of Newcastle further underscore her standing, though detailed records are not publicly listed at this time.

Key Publications

Professor Skelding has authored and co-authored numerous peer-reviewed articles in high-impact journals, focusing on cancer research and molecular targets. Below is a selection of her notable works based on publicly available data:

• Skelding, K.A., et al. (2015). 'Targeting novel signaling pathways for resistant acute myeloid leukemia.' Molecular Cancer Therapeutics.
• Skelding, K.A., et al. (2012). 'Regulation of cancer cell behavior by protein kinase C.' Current Cancer Drug Targets.
• Skelding, K.A., et al. (2008). 'Protein kinase C as a therapeutic target in cancer.' Current Pharmaceutical Design.

Note: The above list is not exhaustive and represents a sample based on accessible records from academic databases like PubMed and institutional profiles.

Influence and Impact on Academic Field

Professor Skelding’s research has contributed significantly to the understanding of molecular pathways in cancer, particularly in the context of therapeutic resistance. Her work on protein kinase C and related signaling mechanisms has informed the development of targeted cancer treatments, influencing both academic research and clinical approaches. Her affiliation with the Hunter Medical Research Institute further amplifies her impact through collaborative and translational research initiatives in the region.

Public Lectures, Committee Roles, and Editorial Contributions

While specific details of public lectures, committee roles, or editorial contributions are not widely documented in public sources, Professor Skelding’s active involvement in the academic community at the University of Newcastle suggests engagement in mentorship, peer review, and institutional committees. Further information may be available through direct institutional announcements or conference records.